Federal Schedule I

The Drug Enforcement Administration (DEA) will hold its first hearing on December 2 to address the Biden administration’s proposal to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). The hearing, announced through a public advisory on November 26...

In a rarely seen legal battle unfolding in a DEA courtroom in Arlington, Virginia, the future of two key psychedelic research compounds, DOI and DOC, hangs in the balance. The DEA's move to classify the substances as Schedule I drugs has sparked fierce resistance from researchers, neuroscientists...

A new study published in AJOB Neuroscience reveals that most Americans are supportive of psilocybin use, a psychedelic compound derived from "magic mushrooms," in supervised, licensed settings. As PsyPost reported, this approval, spanning across political lines, underscores public openness to the...

As psilocybin slowly gains acceptance as a potential mental health treatment, websites claiming to sell magic mushrooms are multiplying online, operating in a gray area of legality. As DoubleBlind reported, while psilocybin remains a Schedule I substance in the U.S., these sites are capitalizing on...

Dr. Sunil Aggarwal’s long-standing battle for the federal rescheduling of psilocybin for end-of-life cancer patients just hit another obstacle. What Happened: According to Marijuana Moment, the Washington-based doctor began seeking permission to provide the therapy from state and federal...

On Dec. 12, the Drug Enforcement Administration (DEA) and the Justice Department jointly released a proposed rule to place 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I under the federal Controlled Substances Act (CSA). Both DOI and DOC are...

The Drug Enforcement Administration (DEA) is pulling back efforts to list certain hallucinogens as Schedule I substances after being challenged by scientists. “DOI and DOC are incredible tools for research, as well as mental and physical health,” Panacea Plant Sciences CEO David...

Amazon.com, Inc. (NASDAQ: AMZN) announced its support on Tuesday for a Republican-backed congressional bill that would cannabis at the federal level and let states decide how and whether to ban or regulate it.  Congresswoman Nancy Mace's (R-SC) State Reform Act,...